The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine has previously been demonstrated to improve survival rates in this population, but the optimal dosing schedule is not well established. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the randomized Phase II trial (NCT01786343) comparing 5-day vs. 10-day dosing regimens of decitabine in older treatment-naïve AML patients. Dr Ravandi also discusses the possible explanations for the differing response rates between this study and previously conducted studies.
